PGD(2)/DP1 Signaling Deficiency Ameliorates Experimental Autoimmune Encephalitis

Jian Zheng,Stanley Perlman
DOI: https://doi.org/10.4049/jimmunol.202.supp.183.7
2019-01-01
Abstract:Abstract D-prostanoid receptor 1 (DP1) is a myeloid cell-expressing receptor of prostaglandin D2 (PGD2), the most abundant prostaglandin in the brain. PGD2/DP1 signaling, which triggers G protein activation and cAMP production, is associated with neuroprotection after ischemia, astrogliosis and demyelination in mice. In our previous study, PGD2/DP1 signaling was found to suppress mouse hepatitis virus (MHV)-induced central nervous system (CNS) inflammasome activation through up-regulating PYDC3 expression in CD11b+ cells. In this study, we now investigated the role of PGD2/DP1 signaling in active experimental autoimmune encephalitis (EAE). In contrast to their enhanced susceptibility to virus-induced CNS inflammation, DP-1−/− mice showed resistance to MOG35–55 peptide-induced EAE, which was characterized by milder demyelination and improved remyelination compared to wild type mice. The amelioration of CNS injury resulted from less infiltration of leukocytes and of activation of microglia and macrophages in the brain and spinal cord. On the other hand, in draining lymph nodes (DLN) of immunized DP-1−/− mice, myeloid cells (macrophages, neutrophils and dendritic cells (DCs)) exhibited highly pro-inflammatory phenotypes, which correlated with activation-induced apoptosis of MOG35–55 peptide-specific T cells. Finally, conditional deletion of DP-1−/− in either microglial (CX3CR1+ cells) or macrophage/monocyte/granulocyte (Lyz2tm1+ cells) failed to ameliorate EAE, suggesting involvement of a different DP1-expressing cell. Ongoing research is directed at determining this critical cell type.
What problem does this paper attempt to address?